Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cantor Fitzgerald
Boehringer Ingelheim
Dow
Baxter
Citi
QuintilesIMS
Colorcon
US Army

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,865,730

« Back to Dashboard

Which drugs does patent 8,865,730 protect, and when does it expire?

Patent 8,865,730 protects ZYDELIG and is included in one NDA.

This patent has thirty patent family members in twenty-five countries.
Summary for Patent: 8,865,730
Title:Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-on- e
Abstract: Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-on- e, compositions thereof, methods for their preparation, and methods for their use are disclosed.
Inventor(s): Carra; Ernest (Foster City, CA), Gerber; Michael (Oakland, CA), Shi; Bing (Redwood city, CA), Sujino; Keiko (Edmonton, CA), Tran; Duong (Edmonton, CA), Wang; Fang (Foster City, CA), Evarts; Jerry B. (Redmond, WA)
Assignee: Gilead Calistoga LLC (Foster City, CA)
Application Number:13/786,222
Patent Claim Types:
see list of patent claims
Compound; Formulation; Composition; Dosage form; Use;

Drugs Protected by US Patent 8,865,730

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL ➤ Try a Free Trial
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,865,730

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,469,643 Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-on- e ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,865,730

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 201350486 ➤ Try a Free Trial
Singapore 11201405446P ➤ Try a Free Trial
Philippines 12014501920 ➤ Try a Free Trial
Peru 17922014 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
UBS
Mallinckrodt
US Department of Justice
McKesson
Cerilliant
Dow
Citi
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.